Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

266.35
-0.7300-0.27%
Post-market: 266.700.3500+0.13%17:17 EDT
Volume:4.85M
Turnover:1.29B
Market Cap:641.72B
PE:30.84
High:271.27
Open:270.21
Low:265.72
Close:267.08
52wk High:281.07
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.75
T/O Rate:0.20%
Dividend:5.24
Dividend Rate:1.97%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.55
PE(LYR):24.14

Loading ...

Johnson & Johnson is Maintained at Overweight by Wells Fargo

Dow Jones
·
Aug 03

Achieve Life Sciences Names Ronald Dadino SVP of CMC and Supply Chain

Reuters
·
Aug 03

Lipocine Appoints Ex-J&J Executive Michael Grissinger to Board

Reuters
·
Aug 03

Eli Lilly Stock Leads 3 Pharma Picks As Merger Talk Shakes Big Drugmakers

Simply Wall St.
·
Aug 03

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

TIPRANKS
·
Aug 03

Perrigo Co. PLC Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

The Week in Breakingviews: Wall Street Rainstorms

Reuters
·
Aug 01

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Benzinga
·
Aug 01

Stryker Beats Quarterly Estimates on Strong Demand for Medical Devices

Reuters
·
Jul 31

Johnson & Johnson Stock (JNJ) Moved Down by 3.49% on Jul 30: Key Drivers Unveiled

TradingKey
·
Jul 31

Movement Alert|Johnson & Johnson Falls 3.23% in Regular Trading, $2.58 Billion Sail Biomedicines Acquisition Option Sparks Short-Term Earnings Dilution Concerns

Market Focus
·
Jul 30

Sector Update: Healthcare

MT Newswires Live
·
Jul 30

Johnson & Johnson’s Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) Receives U.S. FDA Priority Review as Potential First-in-Class Egfr- and Met-Targeted Subcutaneous Treatment for Advanced Head and Neck Cancer

THOMSON REUTERS
·
Jul 30

PRESS Digest -Wall Street Journal - July 30

Reuters
·
Jul 30

Dow Jones Top Company Headlines at 9 PM ET: Samsung's Chip Earnings Push Net Profit to Record | Microsoft ...

Dow Jones
·
Jul 30

Johnson & Johnson Updates Guidance After Firefly, Sail Deals

TIPRANKS
·
Jul 30

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

THOMSON REUTERS
·
Jul 30

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

TIPRANKS
·
Jul 30

Johnson & Johnson Partners with Sail Biomedicines on in Vivo CAR-T Programs, Takes Option to Buy Sail for $2.58 Billion

Reuters
·
Jul 30

Johnson & Johnson Makes $465 Million Equity Investment in Sail Biomedicines

Reuters
·
Jul 30